CHKB
protein-codingcholine kinase beta
Gene summary
Choline kinase (CK) and ethanolamine kinase (EK) catalyze the phosphorylation of choline/ethanolamine to phosphocholine/phosphoethanolamine. This is the first enzyme in the biosynthesis of phosphatidylcholine/phosphatidylethanolamine in all animal cells. The highly purified CKs from mammalian sources and their recombinant gene products have been shown to have EK activity also, indicating that both activities reside on the same protein. The choline kinase-like protein encoded by CHKL belongs to the choline/ethanolamine kinase family; however, its exact function is not known. Read-through transcripts are expressed from this locus that include exons from the downstream CPT1B locus. [provided by RefSeq, Jun 2009]
- CHKL
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~22.5 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0011246
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0011246
Submitter: Labcorp Genetics (formerly Invitae)
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Dermatologic; Musculoskeletal; Neurologic
Intervention: Cardiovascular
Rationale: The condition can include cardiac sequelae (eg, cardiomyopathy and arrhythmias), and surveillance (eg, with echocardiogram and electrocardiogram) can allow potentially beneficial medical interventions
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to CHKB variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_005198.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 3 | 89 | 2 | 94 | ||
| missense | 1 | 2 | 155 | 10 | 2 | 170 |
| nonsense | 11 | 4 | 1 | 16 | ||
| start loss | 1 | 1 | ||||
| frameshift | 13 | 5 | 18 | |||
| splice donor/acceptor (+/-2bp) | 4 | 6 | 2 | 12 | ||
| Total | 29 | 17 | 162 | 99 | 4 | 311 |
Highest pathogenic variant AF is 0.000086175045
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_005189.2 | 11 | MANE Select | |
| Ensembl | ENSP00000384400.3 | 11 | MANE Select | |
| Ensembl | ENSP00000555936.1 | 11 | Standard | |
| Ensembl | ENSP00000555936.1 | 11 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Glycerophospholipid metabolism - Homo sapiens (human)
- Choline metabolism in cancer - Homo sapiens (human)
- Fatty Acid Beta Oxidation
- Kennedy pathway from Sphingolipids
- One carbon metabolism and related pathways
Biological Process
- phosphatidylethanolamine biosynthetic process
- phosphatidylcholine biosynthetic process
- CDP-choline pathway
- phosphorylation
Molecular Function
- choline kinase activity
- ethanolamine kinase activity
- ATP binding
Cellular Component
- cytosol
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000406938
- Coding exons
- 11
- Length
- 22507
- Individuals with no LoFs
- 125709
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 39
- Defined
- 125748
- p
- 0.000155
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.533 | 236 | 214 | 1.10 | 0.0000120 | 2526 |
| Missense (PolyPhen) | 77 | 75.957 | 1.0137 | 922 | ||
| Synonymous | 0.488 | 84 | 89.9 | 0.934 | 0.00000506 | 760 |
| Loss of Function | 1.88 | 14 | 23.9 | 0.586 | 0.00000113 | 266 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00014 | 0.00012 | rare |
| Latino/Admixed American | 0.00023 | 0.00023 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00055 | 0.00054 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.00013 | 0.00013 | rare |
| South Asian | 0.000098 | 0.000098 | rare |
| Other | 0.00016 | 0.00016 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Has a key role in phospholipid biosynthesis. Catalyzes the first step in phosphatidylethanolamine biosynthesis. Phosphorylates ethanolamine, and can also act on choline (in vitro). Has higher activity with ethanolamine. May not significantly contribute to in vivo phosphatidylcholine biosynthesis. {ECO:0000269|PubMed:19915674}.;
Recessive Scores
- pRec
- 0.121
Intolerance Scores
- LoFtool
- 0.847
- RVIS EVS
- -0.31
- RVIS percentile EVS
- 31.93
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.292
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |